1. P664 SB5 and reference adalimumab show cross-immunogenicity in patients with inflammatory bowel disease or rheumatoid arthritis. (25th January 2019) Authors: Gonçalves, J; Myung, G; Hong, E; Park, M; Jeong, D; Ghil, J Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S451 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0169 Maintenance and improvement in clinical efficacy between week 12 and 24 in patients with rheumatoid arthritis treated with sb4 or reference etanercept. (15th June 2017) Authors: Emery, P; Vencovsky, J; Keystone, E; Ghil, J; Cheong, SY; Hong, EE Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 834 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0198 Usability and safety of SB5 (an adalimumab biosimilar) pre-filled syringe and pre-filled pen in patients with rheumatoid arthritis. (15th June 2017) Authors: Ghil, J; Niebrzydowski, J; Zielińska, A; Lee, Y Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 556 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP0204 Impact of anti-drug antibody and injection site reaction on efficacy: 24-week results from a phase iii study comparing SB4 (etanercept biosimilar) with reference etanercept in patients with rheumatoid arthritis. (15th June 2017) Authors: Vencovsky, J; Emery, P; Keystone, E; Ghil, J; Cheong, SY; Hong, EE Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OP0203 Impact of adalimumab serum concentration on efficacy and association between ANTI-DRUG antibodies and serum concentration: 24 week results from a phase III study comparing SB5 (an adalimumab biosimilar) with reference adalimumab in patients with rheumatoid arthritis. (15th June 2017) Authors: Kay, J; Weinblatt, M; Keystone, E; Genovese, M; Ghil, J; Cheong, SY; Hong, EE Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis. (2nd September 2020) Authors: Emery, P; Suh, C-H; Weinblatt, ME; Smolen, JS; Keystone, EC; Genovese, M; Vencovsky, J; Kay, J; Hong, E; Baek, Y; Ghil, J Journal: Scandinavian journal of rheumatology Issue: Volume 49:Number 5(2020) Page Start: 361 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis. (2nd September 2020) Authors: Emery, P; Suh, C-H; Weinblatt, ME; Smolen, JS; Keystone, EC; Genovese, M; Vencovsky, J; Kay, J; Hong, E; Baek, Y; Ghil, J Journal: Scandinavian journal of rheumatology Issue: Volume 49:Number 5(2020) Page Start: 361 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗